TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Interventions in Irritable Bowel Syndrome: Soluble, Insoluble or no Fibre?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18-65 years presenting to their General Practitioner (GP) with either incident IBS symptoms or with a relapse of pre-existing IBS as well as patients with a prior GP diagnosis of IBS and currently experiencing symptoms are eligible for the study. Patients will be stratified in two equally large patients groups of (a) 'definite' IBS, according to the Rome II diagnostic criteria, and (b) 'probable' IBS, pragmatically diagnosed with IBS by their GP.~Exclusion Criteria:~* Patients treated with fibre in the prior 4 weeks~* Patients with alarm symptoms i.e. abnormalities at physical examination, fever, weight loss, rectal bleeding, acute abdominal pain~* Patient with fibre intolerance~* Patients treated for Irritable Bowel Syndrome by a specialist in the prior 48 months~* Patients with active psychiatric disorder requiring medication~* Patients not able to fill out the questionnaires

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* children and adolescents (aged 6 to less than 18 years) with Familial Hypercholesterolaemia~* Patients aged between 6 and less than 10 years of age must not be taking a statin medicine~Exclusion Criteria:~* History of muscle or sensitivity reactions to any statin medicines~* Current active liver disease or dysfunction (except a confirmed diagnosis of Gilbert's disease)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects are between 18 and 55 years of age (inclusive)~* Subjects have a Body Mass Index (BMI) between 18 and 35 kg/m\^2 (inclusive)~* Subjects must be in generally good health with no clinically relevant health conditions~Exclusion Criteria:~* Subject has previously been randomized in this study or subject has received LCM or CBZ~* Subjects may not currently be participating in or have participated in the past 30 days in a clinical drug or device study~* Subjects may not have a history of drug or alcohol abuse within the last 2 years~* Subjects may not consume more than 40 g of alcohol per day~* Females who are pregnant or nursing are ineligible; females of childbearing potential must agree to adhere to protocol conception guidelines~* Subjects may not score ≤ 70 on the Peabody Picture Vocabulary Test (PPVT)~* Subjects with a lifetime history of suicide attempt or suicidal ideation in the past 6 months may not participate~* Subjects with a diet that deviates notably from the normal amounts of protein, carbohydrate, and fat, as judged by the investigator are ineligible to participate~* Subjects may not consume more than 600 mg of caffeine/day~* Subjects may not smoke more than 10 cigarettes per day or have done so within 6 months prior to Screening~* Subjects may not have a positive alcohol breath test or urine drug screen at Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- LCM 300 mg/CBZ-IR 600 mg (Type: OTHER): Crossover sequence of experimental treatment and active comparator
- CBZ-IR 600 mg/LCM 300 mg (Type: OTHER): Crossover sequence of active comparator and experimental treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Routine Nebulization of Mucolytics and Bronchodilators During Mechanical Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 year or older~* Expected duration of intubation and ventilation \> 24 hours~* Written informed consent~Exclusion Criteria:~* Age less than 18 years~* Ventilation before present ICU admission (though short-term ventilation in the emergency room or in the operation room for general anesthesia during surgery is allowed)~* Suspected or confirmed pregnancy~* Diagnosed with lung diseases for which inhalation therapy and/or oral steroids are used~* Diagnoses of: Guillain-Barré syndrome, complete spinal cord lesion or amyotrophic lateral sclerosis, Multiple Sclerosis, Myasthenia Gravis~* Known allergy for acetylcysteine or salbutamol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- acetylcysteine and salbutamol (Type: ACTIVE_COMPARATOR): Nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator), administered every 6 hours (i.e., 4 times per day) within 24 hours after initiation of ventilation until tracheal extubation.
- acetylcysteine or salbutamol (Type: EXPERIMENTAL): Nebulisation on strict clinical indications; nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) in case of occurrence of persistent thick and tenacious sputum and only after active humidification is set.~Nebulisation of 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator) in case of occurrence of bronchospasm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples (SAFER)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~For all couples:~* Couple expresses a desire to conceive~* Sexually active (defined as having vaginal sex with one another at least 6 times in the past 3 months~* Willing to enter the study as a couple and intending to remain as a couple and have a sexual relationship for the next 12 months~* Willing to use at least one safer conception strategy~* For men, age ≥18 years. For women, age 18 - 35 years;~* Able and willing to provide written informed consent~For HIV-uninfected members of the couple~* HIV-negative based on parallel negative HIV rapid tests, both at study screening and enrollment visit~* Adequate renal function, defined by normal creatinine levels and estimated creatinine clearance ≥60 mL/min~For HIV-infected members of the couple~* HIV-positive based on parallel positive HIV rapid tests, based on national algorithm~* No current AIDS-defining illness~Exclusion Criteria:~* Amenorrheic~* Currently pregnant~* Active and serious infections, including active tuberculosis infection; active clinically significant medical problems including cardiac disease, pulmonary disease, and previously diagnosed malignancy expected to require further treatment.~* History of infertility defined as a year or more of regular unprotected intercourse with current partner without pregnancy, or otherwise medically diagnosed infertility~* Currently on any concomitant medication that requires the participant to avoid use of PrEP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- HIV+male/HIV-female (Type: None): discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or semen washing
- HIV+female/HIV-male (Type: None): discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or artificial vaginal insemination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* chronic renal anemia;~* hemodialysis 3 times weekly for \>=12 weeks before screening, and during screening/baseline period;~* receiving darbepoetin alfa maintenance therapy for \>=8 weeks before screening, and during screening/baseline period.~Exclusion Criteria:~* overt gastrointestinal bleeding within 8 weeks before screening or during screening/baseline period;~* transfusion of red blood cells within 8 weeks before screening or during screening/baseline period;~* active malignancy;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MIRCERA (Type: EXPERIMENTAL): Eligible participants with anemia in CKD who were on hemodialysis will receive methoxy polyethylene glycol-epoetin beta (MIRCERA \[RO0503821\]) IV once every month up to 52 weeks. The starting dose of MIRCERA which will be administered during the treatment period will depend on the dose of darbepoetin alfa administered during screening period i.e., 120, 200 and 360 mcg for weekly darbepoetin alfa doses of \<40, 40-80, and \>80 mcg, respectively.
- Darbepoetin Alfa (Type: ACTIVE_COMPARATOR): Eligible participants with anemia in CKD who were on hemodialysis will receive darbepoetin alfa (Aranesp) IV once every two weeks up to 26 weeks and darbepoetin alfa IV twice the dose than earlier, once every month from Week 27 up to Week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* ECOG Status: PS 0-1 \& PS 2~* Subjects with histologically or cytologically-documented SqNSCLC~* Subjects must have experienced disease progression or recurrence during or after one prior platinum doublet-based chemotherapy regimen~* Subjects must have evaluable disease by CT or MRI per RECIST 1.1 criteria~* Subjects with treated or asymptomatic CNS metastases~* Prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration~* Prior lines of antineoplastic therapy, including hemotherapy, hormonal therapy, immunotherapy, surgical resection of lesions, non-palliative radiation therapy, or standard or investigational agents for treatment of NSCLC, must be completed 28 days prior to the first dose of nivolumab~* Males and Females, ages 18 or older~Exclusion Criteria:~* Subjects with untreated, symptomatic CNS metastases~* Subjects with carcinomatous meningitis~* Subjects with active, known or suspected autoimmune disease.~* Subjects who received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways) or who have previously taken part in a randomized BMS clinical trial for nivolumab or ipilimumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A: Treatment - Nivolumab (Type: EXPERIMENTAL): Nivolumab IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fixed Dose Heparin Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of acute venous thromboembolism (VTE,DVT and /or PE)~Exclusion Criteria:~* Contraindication to subcutaneous (sc) route of administration (eg:shock (evidence of poor peripheral perfusion), major surgery within 48 hours)~* Active Bleeding process~* Comorbid condition limiting expected survival to less than 3 months~* Current treatment with therapeutic dose of UFH, LMWH, danaparoid sodium, or a direct thrombin inhibitor for more than 48 hours~* Currently on long term warfarin or heparin therapy~* Allergy to heparin or history of heparin induced thrombocytopenia~* Currently pregnant~* Contraindication to contrast media (eg: allergy or creatinine \>200 umol/L).~* Currently enrolled or will be enrolled in a competing study~* Geographically inaccessible for follow-up assessment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Has signed a written informed consent prior to the first study evaluation;~2. Male or female is at least 20 and \< 80 years of age;~3. Diabetes mellitus (type 1 or 2) with an HbA1c \< 12.0% measured during screening or within three months prior to randomization;~4. An ankle brachial index on the target limb at least 0.8 measured during screening or within three months prior to randomization;~5. The target ulcer must have the following characteristics:~   * Grade 1 or 2 per Wagner Ulcer Classification System;~  * No higher than the ankle;~  * No active infected;~  * A cross-sectional area of between 1 and 25 cm2 post-debridement;~  * Present for at least 4 weeks before randomization;~6. If female and of childbearing potential has a negative pregnancy test and is not breastfeeding at screening visit;~7. Able and willing to attend the scheduled visits and comply with study procedures.~Exclusion Criteria:~1. Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement;~2. Acute Charcot's neuroarthropathy as determined by clinical and/or radiographic examination;~3. Has undergone revascularization procedure aimed at increasing blood flow in the treatment target limb \< 4 weeks prior to randomization;~4. Poor nutritional status defined as an albumin \< 2.5 g/dL;~5. Aspartate Aminotransferase(AST, GOT) and/or Alanine Aminotransferase(ALT, GPT) \>3 x the normal upper limit;~6. Serum Creatinine \>2 x the normal upper limit;~7. Treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 4 weeks before randomization;~8. Use of any investigational drug or therapy within the 4 weeks prior to randomization;~9. A psychiatric condition (e.g., suicidal ideation), current or chronic alcohol or drug abuse problem, determined from the subject's medical history, which, in the opinion of the Investigator, may pose a threat to subject compliance;~10. Judged by the investigator not to be suitable for the study for any other reason.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ON101 Cream (Type: EXPERIMENTAL): ON101 Cream (1.25%),15g ointment per tube. Twice daily for up to 16 weeks.
- Aquacel® Hydrofiber® dressing (Type: OTHER): Aquacel® Hydrofiber® dressings will be changed daily, on alternate days or three times a week according to need, but not longer than 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir Tablet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Non-smoking, or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months prior to selection~* Normal weight as defined by a Body Mass Index (BMI, weight in kg divided by the square of height in meters) of 18.0 to 30.0 kg/m2, extremes included~* Able to comply with protocol requirements. Healthy on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality and includes a physical examination, medical history, electrocardiogram (ECG), vital signs, and the results of blood biochemistry, blood coagulation, and hematology tests and a urinalysis carried out at screening.~Exclusion Criteria:~* No positive HIV 1 or HIV 2 test at screening~* no history of significant skin disease such as, but not limited to rash or eruptions, drug allergies, food allergy, dermatitis, eczema, psoriasis, or urticaria~* no history of allergy to drugs such as, but not limited to, sulphonamides and penicillins~* no previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the investigational medication administered in this trial~* no female subject of childbearing potential without use of effective nonhormonal birth control methods, or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period~* no positive pregnancy test or breast feeding at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects enrolled in the Y-47-52120-051 study, who have completed all study visits up to Week 12, or up to Week 4 in the event of an early withdrawal~* Returned to pre-treatment status as judged by the Investigator~Exclusion Criteria:~* Pure anterocollis or pure retrocollis~* Known antibodies to botulinum toxin type A~* Requirement for botulinum toxin injections to site(s) other than the neck and unable to avoid such treatment for the duration of the study~* Known significant underlying swallowing or respiratory abnormality which might be exacerbated by botulinum toxin treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dysport (Type: EXPERIMENTAL): 250-1000 units

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has signed and dated the informed consent.~* Patient has up to 2 documented stenotic or occluded atherosclerotic lesions (up ro 14 cm long) of the above-the-knee femoropopliteal artery, up to one in each limb, that meet all of the inclusion criteria and none of the exclusion criteria.~* Patient has a de novo or restenotic lesion(s) with \>50% stenosis documented angiographically and no prior stent in the target lesion.~* Patient has symptoms of peripheral arterial disease classified as Rutherford Category 2 or greater.~* Patient has a resting Ankle Brachial Index (ABI) \<0.9 or an abnormal exercise ABI if resting ABI is normal. Patient with incompressible arteries (ABI \>1.2) must have a Toe Brachial Index (TBI) \<0.8.~* Patient agrees to return for a clinical status assessment and duplex ultrasound at 6 months, 12 months, and at 2, 3, 4, and 5 years.~* Patient agrees to return for x-rays at 6 and 12 months.~* Patient agrees to return for angiography at 12 months.~* Patient agrees to be contacted by telephone at 1, 3, 9, and 18 months to assess clinical status.~Exclusion Criteria:~* Patient is pregnant or breast-feeding.~* Patient is simultaneously participating in another investigational drug or device study.~* Patient has significant stenosis or occlusion of inflow tract not successfully treated before this procedure.~* Patient has any planned surgical or interventional procedure within 30 days after the study procedure.~* Patient has had previous stenting of target vessel.~* Patient in whom antiplatelet and/or anticoagulant therapy is contraindicated.~* Patient has known hypersensitivity or contraindication to aspirin, antiplatelet medication, contrast dye, paclitaxel or nitinol and, in the opinion of the investigator, cannot be adequately premedicated.~* Patient lacks at least one patent vessel of runoff with \<50% stenosis throughout its course.~* Patient has untreated angiographically-evident thrombus in the target lesion.~\[Additional criteria may apply.\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Zilver® PTX™ Drug Eluting Vascular Stent
- 2 (Type: ACTIVE_COMPARATOR): Angioplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete